Logo

pertuzumab

SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance

Genomic sequencing on 733 HER2-positive advanced breast cancer patients revealed mechanisms of anti-HER2 treatment resistance and potential therapeutic solutions.

Roche Q3 Pharmaceutical Revenues Grow 5 Percent Helped by Precision Cancer Drugs

HER2-targeted breast cancer drugs and the immunotherapy Tecentriq were among the top-selling therapies during the quarter.

Roche Q2 Pharmaceutical Revenues Increase 4 Percent

Increasing revenues from newer oncology drugs like atezolizumab and strong diagnostics division revenues helped diminish the impact of the pandemic.

Genentech Basket Trial Identifies Impact of Co-Mutations in Dual HER2-Targeted Treatment Response

Researchers studying Perjeta and Herceptin in HER2-positive advanced solid tumors reported that the combination is efficacious in KRAS wild-type tumors.

Genentech Garners FDA Approval for Skin-Injectable Phesgo in HER2-Positive Breast Cancer

Healthcare professionals can inject the regimen, containing Perjeta, Herceptin, and hyaluronidase, in patients' homes after intravenous chemotherapy.